QIAGEN
ISIN NL0015002CX3
|WKN A40ZZU
Overview
Description
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Healthcare Healthcare Equipment Diagnostics and Drug Delivery Devices Netherlands
Financials
Key metrics
| Market capitalisation, EUR | 8,045.77 m |
| EPS, EUR | 0.34 |
| P/B ratio | 2.56 |
| P/E ratio | 110.61 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 1,828.81 m |
| Net income, EUR | 77.28 m |
| Profit margin | 4.23% |
What ETF is QIAGEN in?
There are 303 ETFs which contain QIAGEN. All of these ETFs are listed in the table below. The ETF with the largest weighting of QIAGEN is the iShares TecDAX UCITS ETF (DE).
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
